What IBcause™ Tests for

IBcause™ helps doctors diagnose common underlying causes (the “troublemakers”) of persistent diarrhea, including gastrointestinal (GI) pathogens (eg, bacteria, viruses, and parasites), intestinal inflammation associated with inflammatory bowel disease (IBD), bile acid malabsorption, irritable bowel syndrome (IBS), and celiac disease.1-6

It analyzes a unique combination of 20 stool and blood measures all at 1 time. By combining so many different measures in 1 convenient test, IBcause™ may help speed up the step-by-step diagnostic process. It also helps your doctor determine if you have more than 1 issue that could be causing your persistent diarrhea, which is not uncommon.7

IBcause™ may help your doctor:
  • Arrive at a diagnosis faster*
  • Start you on the right treatment plan sooner
With IBcause, over 90% of acute diarrhea-causing agents can be ruled out by your doctor.8

Tests for GI pathogens

Bad “bugs” (pathogens) are common troublemakers that cause persistent diarrhea.4,9 They are really easy to pick up, especially when traveling outside the United States.1,4,9,10 IBcause™ has proven technology that tests for multiple pathogens that may be in your body at the same time, including 8 types of bacteria, 3 types of parasites, and 3 types of viruses.1,11

Tests for intestinal inflammation

Intestinal inflammation is common in people who suffer from inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis.12 The inflammation can occur in 1 specific place or all throughout the GI tract. It can also cause all kinds of uncomfortable symptoms, including diarrhea.12

IBcause™ tests for a substance in your stool called fecal calprotectin, a biomarker that helps your doctor know if you have intestinal inflammation, which may be associated with IBD.13 Measuring different substances within the body may help doctors know if a disease or a condition is present.9,13,14

Tests for bile acid malabsorption15

Bile acids are substances (molecules) in the body that work to break down fatty acids in the fats and oils you eat.15,16 When the levels of bile acids are too high in your body, especially in your bowel, it may result in persistent diarrhea.15,16 It’s pretty common: signs of a bile acid absorption problem (called bile acid malabsorption) may be seen in up to 50% of people who have unexplained persistent diarrhea.15 It’s also often overlooked or misdiagnosed as IBS-D (irritable bowel syndrome with diarrhea).17,18

Tests for celiac disease

Celiac disease is often an inherited condition where exposure to gluten in certain foods (such as those made with wheat, bulgur, barley, and rye) causes an unwanted autoimmune attack within the lining of the small intestine. It can cause diarrhea, and if left untreated, may lead to serious health issues.19 IBcause™ analyzes multiple diagnostic measures that are associated with celiac disease.

If an immediate family member (mom, dad, child, brother, or sister) has celiac disease, you have a 1 in 10 chance of having it, too.20

Helps to point to irritable bowel syndrome

Persistent diarrhea is pretty common to yet another uncomfortable condition: irritable bowel syndrome (IBS).21 IBS often involves a slow process of testing1,2,22 and eliminating different conditions21 before a diagnosis is made. IBcause™ may help your doctor speed up this process to get the answers you both want.

Approximately 14% of all Americans have IBS.20,23,24

What is IBcause?

What is IBcause?

IBcause™ is a blood and stool test. Your doctor may order 1 or both of these parts depending on your symptoms and medical history.

The blood portion of IBcause™ is a simple blood draw. The stool portion of IBcause™ is an at-home stool sample kit. This kit will help make your stool collection as easy as possible. After collecting your sample, you simply ship the prepaid labeled box back to Prometheus for testing. Everything is provided to you, from the kit to step-by-step instructions and the return-shipping box.

After your sample has been tested, your doctor will review your test results and may share them with you. You may also be able to view your results on the Prometheus Online.

IBcause. Because you and your doctor want to know.

*Compared to sequential testing with the standard workup for persistent diarrhea.

Watch the IBcause™ video  


Collecting your sample  

  1. 1.DuPont HL. Persistent diarrhea: a clinical review. JAMA. 2016;315(24):2712-2723.

  2. 2.Juckett G, Trivedi R. Evaluation of chronic diarrhea. Am Fam Physician. 2011;84(10):1119-1126.

  3. 3.Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol. 2012;18(42):6036-6059.

  4. 4.Hodges K, Gill R. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes. 2010;1(1):4-21.

  5. 5.Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012;18(3):258-268.

  6. 6.Barkun AN, Love J, Gould M, Pluta H, Steinhart H. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol. 2013;27(11):653-659.

  7. 7.Data on file, Prometheus Laboratories Inc.

  8. 8.Luminex Corporation. xTAG® Gastrointestinal Pathogen Panel (GPP). 2014.

  9. 9.Navaneethan U, Giannella RA. Definition, epidemiology, pathophysiology, clinical classification, and differential diagnosis of diarrhea. In: Guandalini S, Vaziri H, eds. Diarrhea: Diagnostic and Therapeutic Advances. New York, NY: Humana Press; 2011:1-31.

  10. 10.Guandalini S. Probiotics for diarrheal diseases. In: Guandalini S, Vaziri H, eds. Diarrhea: Diagnostic and Therapeutic Advances. New York, NY: Humana Press; 2011:459-474.

  11. 11.Luminex [package insert]. Toronto, ON, Canada: Luminex Molecular Diagnostics, Inc.; 2014.

  12. 12.Inflammatory bowel disease (IBD). Mayo Clinic Web site. www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/basics/definition/con-20034908?p=1. Published February 18, 2015. Accessed January 18, 2017.

  13. 13.Benítez JM, García-Sánchez V. Faecal calprotectin: management in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;15;6(4):203-209.

  14. 14.Amaratunge C, Sellin JH. Evaluation of patients with diarrhea and timing of referral. In: Guandalini S, Vaziri H, eds. Diarrhea: Diagnostic and Therapeutic Advances. New York, NY: Humana Press; 2011:431-442.

  15. 15.Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332-339.

  16. 16.Clinical updates: tests aid diagnosis of an under-recognized disorder. Mayo Clinic Web site. http://www.mayoclinic.org/medical-professionals/clinical-updates/digestive-diseases/tests-aid-diagnosis-of- an-under-recognized-disorder. Published April 2, 2014. Accessed January 18, 2017.

  17. 17.Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol. 2010;4(5):561-567.

  18. 18.Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull. 2009;92:79-93.

  19. 19.Presutti RJ, Cangemi JR, Cassidy HD, Hill DA. Celiac disease. Am Fam Physician. 2007;76(12):1795-1802.

  20. 20.What is celiac disease? Celiac Disease Foundation Web site. https://celiac.org/celiac-disease/understanding-celiac-disease-2/what-is-celiac-disease. Accessed January 18, 2017.

  21. 21.Diseases and conditions: irritable bowel syndrome. Mayo Clinic Web site. www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/definition/con-20024578?p=1. Published July 31, 2014. Accessed January 18, 2017.

  22. 22.Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6):1464-1486.

  23. 23.Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292(7):852-858.

  24. 24.Talley NJ. New and important insights into IBS: from epidemiology to treatment. Medscape Web site. http://www.medscape.org/viewarticle/444514. Published November 25, 2002. Accessed January 18, 2017.